TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02676765
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
Study: NCT00686361
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
Study: NCT04274257
Drug: Double-Blind Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered.
Study: NCT01207089
Drug: AZD8329
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8329 Oral Solution 20mg/ml
Study: NCT01207089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo AZD8329 Oral Solution
Study: NCT03522831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
Study: NCT04800679
Drug: PRP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
Study: NCT00104494
Drug: Zinc acetate (20mg/d)
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
Study: NCT00913718
Drug: Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913718
Drug: Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
Normalized name: fluoxetine Oral Capsule [Prozac]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00536042
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: addition of 150 mg to 250 mg po bid to standard asthma care regiment
Study: NCT04105205
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min infusion
Study: NCT02108184
Drug: Sequential therapy 10 days
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
Study: NCT02108184
Drug: Sequential therapy 14 days
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
Study: NCT02108184
Drug: Concomitant therapy 10 days
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
Study: NCT02108184
Drug: Concomitant therapy 14 days
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
Study: NCT01026311
Drug: Coenzyme q 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Coenzyme q 10
Study: NCT01026311
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo q d during treatment period
Study: NCT00557089
Drug: rhDNAse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
Study: NCT00400842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04080544
Drug: [18F]AV-1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
Study: NCT03678233
Drug: AndroGel 16.2 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
Study: NCT00463697
Drug: GW642444H (100mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H salt
Study: NCT00463697
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00463697
Drug: GW642444M (25, 100 & 400 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M salt
Study: NCT02867345
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study: NCT00518219
Drug: TW
Normalized name: Etwon
Approvals — FDA: no, EMA: no, PMDA: no
Description: TW,120mg/d
Study: NCT01682499
Drug: calcium gluconate and magnesium sulfate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
Study: NCT00492856
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00492856
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00492856
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00315705
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Study: NCT00148005
Drug: Anticholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02551198
Drug: SUCLEAR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
Study: NCT01919918
Drug: Muscle Contraction with Metabolite Solution Administration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
Study: NCT01346371
Drug: Refresh Tears 0.5% Lubricant Eye Drops
Normalized name: Refresh Tears 0.5% Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01346371
Drug: Bepreve 1.5% Ophthalmic Solution
Normalized name: Bepreve 1.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03508141
Drug: Cryoprecipitate
Normalized name: Cryoprecipitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT02310802
Drug: OBE001 dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE001 dispersible tablets for single oral administration
Study: NCT02310802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dispersible tablets for single oral administration
Study: NCT00338312
Drug: Testosterone Transdermal System
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
Study: NCT00338312
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch changed twice a week for one year
Study: NCT00649779
Drug: VoSpire™ ER 8 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg, single dose fasting
Study: NCT03192527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator.
Study: NCT04641312
Drug: LY3457263
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04641312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00783211
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, once daily for 15 days
Study: NCT01870024
Drug: Fosphenytoin
Normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
Study: NCT01870024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
Study: NCT01658501
Drug: 50 mg PB1023
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01658501
Drug: 70 mg PB1023
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01658501
Drug: 100 mg PB1023
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01658501
Drug: Placebo (0.9% Sodium Chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01658501
Drug: Victoza®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01658501
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01658501
Drug: Metformin and Sulfonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01386255
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo. No other names
Study: NCT04371107
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
Study: NCT00620685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily for 4 weeks
Study: NCT02918812
Drug: Intramuscular Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Diclofenac 30 mins before HSG
Study: NCT01650584
Drug: ISTA Tears
Normalized name: PEG-400/Propylene Glycol 0.4%-0.3% Ophthalmic Solution [VISTA TEARS DRY EYE RELIEF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT00001261
Drug: Gamma Globulin
Normalized name: Gamma globulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03846583
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
Study: NCT00354692
Drug: Sodium Ferric Gluconate and Iron sucrose
Normalized name: FERRIC NA GLUCONATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03544944
Drug: TJP-008-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
Study: NCT03544944
Drug: TJP-008-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
Study: NCT03544944
Drug: Coolprep powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
Study: NCT04504123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03016975
Drug: Guideline Directed Medical Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDMT Only
Study: NCT01590797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily for 24 weeks
Study: NCT00380744
Drug: LY2189102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00380744
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03179423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly IV repeated dose
Study: NCT01338870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (n=4), 0 mg twice daily for 84 days
Study: NCT02730299
Drug: NiCord® (omidubicel)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04368351
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Study: NCT02943590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pill taken once a day
Study: NCT02369302
Drug: DWC20142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02369302
Drug: DWC20141, DWC20142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01233739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 capsules of placebo orally.
Study: NCT00002638
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04218734
Drug: DBPR108
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPR108: 100 mg, once daily for 24 weeks.
Study: NCT04218734
Drug: placepo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo:100 mg, once daily for 24 weeks.
Study: NCT03731442
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
Study: NCT02520518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01346787
Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
Study: NCT02655705
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
Study: NCT00100308
Drug: Unfractioned heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose continuous-infusion, 500 units/hour per seven days
Study: NCT00447876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
Study: NCT04355065
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group.
Study: NCT02432157
Drug: Standard fluid management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid management strategy as pre-specified by our SAH management protocol.
Study: NCT00717379
Drug: Methylprednisolone or equivalent
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01653717
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/kg by vein on Days -5 to -3.
Study: NCT01121081
Drug: Alga Dunaliella Bardawil
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day, 2 in the morning 2 in the evening for 3 month
Study: NCT01121081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month
Study: NCT02422797
Drug: DTG 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Study: NCT02422797
Drug: RPV 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
Study: NCT01038297
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of EXC 001 and placebo given on various schedules.
Study: NCT00446485
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo during 6 months
Study: NCT01038297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of EXC 001 and placebo given on various schedules.
Study: NCT00766779
Drug: Non-Transplant treatment approach for consolidation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
Study: NCT00003577
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003577
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003577
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003577
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04648423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for oral administration
Study: NCT01528007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill with no active ingredients.
Study: NCT04010786
Drug: NNC0247-0829
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
Study: NCT04010786
Drug: Placebo (NNC0247-0829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
Study: NCT03055403
Drug: M201-A Injection
Normalized name: OCTINOXATE 2.45 g in 35 g / TITANIUM DIOXIDE 4.03 g in 35 g / ZINC OXIDE 1.72 g in 35 g / OCTISALATE 1.58 g in 35 g TOPICAL CREAM [15HR COVER LASTING M201 Medium Beige SPF50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: M201-A Route of administration: continuous intravenous injection
Study: NCT03133650
Drug: WST 11-mediated VTP therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
Study: NCT00606164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single one-hour intravenous infusion of placebo on Day 1
Study: NCT00535405
Drug: Ezetimibe 10 mg/simvastatin 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
Study: NCT01496430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02509598
Drug: Vital Blue Dye (optional)
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
Study: NCT00932152
Drug: Best supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
Study: NCT00188877
Drug: cisplatinium and fluorouracil - standard treatment
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00421343
Drug: calcium carbonate with cholecalciferol
Normalized name: calcium carbonate / cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
Study: NCT03423186
Drug: SOBI003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly i.v.infusion
Study: NCT00564330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid